Citizens' Oversight Maryland---Maryland Progressives
CINDY WALSH FOR MAYOR OF BALTIMORE----SOCIAL DEMOCRAT
Citizens Oversight Maryland.com
  • Home
  • Cindy Walsh for Mayor of Baltimore
    • Mayoral Election violations
    • Questionnaires from Community >
      • Education Questionnaire
      • Baltimore Housing Questionnaire
      • Emerging Youth Questionnaire
      • Health Care policy for Baltimore
      • Environmental Questionnaires
      • Livable Baltimore questionnaire
      • Labor Questionnnaire
      • Ending Food Deserts Questionnaire
      • Maryland Out of School Time Network
      • LBGTQ Questionnaire
      • Citizen Artist Baltimore Mayoral Forum on Arts & Culture Questionnaire
      • Baltimore Transit Choices Questionnaire
      • Baltimore Activating Solidarity Economies (BASE)
      • Downtown Partnership Questionnaire
      • The Northeast Baltimore Communities Of BelAir Edison Community Association (BECCA )and Frankford Improvement Association, Inc. (FIA)
      • Streets and Transportation/Neighbood Questionnaire
      • African American Tourism and business questionnaire
      • Baltimore Sun Questionnaire
      • City Paper Mayoral Questionnaire
      • Baltimore Technology Com Questionnaire
      • Baltimore Biker's Questionnair
      • Homewood Friends Meeting Questionnaire
      • Baltimore Historical Collaboration---Anthem Project
      • Tubman City News Mayoral Questionnaire
      • Maryland Public Policy Institute Questionnaire
      • AFRO questionnaire
      • WBAL Candidate's Survey
  • Blog
  • Trans Pacific Pact (TPP)
  • Progressive vs. Third Way Corporate Democrats
    • Third Way Think Tanks
  • Financial Reform/Wall Street Fraud
    • Consumer Financial Protection Bureau >
      • CFPB Actions
    • Voted to Repeal Glass-Steagall
    • Federal Reserve >
      • Federal Reserve Actions
    • Securities and Exchange Commission >
      • SEC Actions
    • Commodity Futures Trading Commission >
      • CFTC Actions
    • Office of the Comptroller of the Currency >
      • OCC Actions
    • Office of Treasury/ Inspector General for the Treasury
    • FINRA >
      • FINRA ACTIONS
  • Federal Healthcare Reform
    • Health Care Fraud in the US
    • Health and Human Services Actions
  • Social Security and Entitlement Reform
    • Medicare/Medicaid/SCHIP Actions
  • Federal Education Reform
    • Education Advocates
  • Government Schedules
    • Baltimore City Council
    • Maryland State Assembly >
      • Budget and Taxation Committee
    • US Congress
  • State and Local Government
    • Baltimore City Government >
      • City Hall Actions
      • Baltimore City Council >
        • Baltimore City Council Actions
      • Baltimore Board of Estimates meeting >
        • Board of Estimates Actions
    • Governor's Office >
      • Telling the World about O'Malley
    • Lt. Governor Brown
    • Maryland General Assembly Committees >
      • Communications with Maryland Assembly
      • Budget and Taxation Committees >
        • Actions
        • Pension news
      • Finance Committees >
        • Schedule
      • Business Licensing and Regulation
      • Judicial, Rules, and Nominations Committee
      • Education, Health, and Environmental Affairs Committee >
        • Committee Actions
    • Maryland State Attorney General >
      • Open Meetings Act
      • Maryland Courts >
        • Maryland Court System
    • States Attorney - Baltimore's Prosecutor
    • State Comptroller's Office >
      • Maryland Business Tax Reform >
        • Business Tax Reform Issues
  • Maryland Committee Actions
    • Board of Public Works >
      • Public Works Actions
    • Maryland Public Service Commission >
      • Public Meetings
    • Maryland Health Care Commission/Maryland Community Health Resources Commission >
      • MHCC/MCHRC Actions
    • Maryland Consumer Rights Coalition
  • Maryland and Baltimore Development Organizations
    • Baltimore/Maryland Development History
    • Committee Actions
    • Maryland Development Organizations
  • Maryland State Department of Education
    • Charter Schools
    • Public Schools
    • Algebra Project Award
  • Baltimore City School Board
    • Charter Schools >
      • Charter Schools---Performance
      • Charter School Issues
    • Public Schools >
      • Public School Issues
  • Progressive Issues
    • Fair and Balanced Elections
    • Labor Issues
    • Rule of Law Issues >
      • Rule of Law
    • Justice issues 2
    • Justice Issues
    • Progressive Tax Reform Issues >
      • Maryland Tax Reform Issues
      • Baltimore Tax Reform Issues
    • Strong Public Education >
      • Corporate education reform organizations
    • Healthcare for All Issues >
      • Universal Care Bill by state
  • Building Strong Media
    • Media with a Progressive Agenda (I'm still checking on that!) >
      • anotherangryvoice.blogspot.com
      • "Talk About It" Radio - WFBR 1590AM Baltimore
      • Promethius Radio Project
      • Clearing the Fog
      • Democracy Now
      • Black Agenda Radio
      • World Truth. TV Your Alternative News Network.
      • Daily Censured
      • Bill Moyers Journal
      • Center for Public Integrity
      • Public Radio International
      • Baltimore Brew
      • Free Press
    • Far Left/Socialist Media
    • Media with a Third Way Agenda >
      • MSNBC
      • Center for Media and Democracy
      • Public Radio and TV >
        • NPR and MPT News
      • TruthOut
  • Progressive Organizations
    • Political Organizations >
      • Progressives United
      • Democracy for America
    • Labor Organizations >
      • United Workers
      • Unite Here Local 7
      • ROC-NY works to build power and win justice
    • Justice Organizations >
      • APC Baltimore
      • Occupy Baltimore
    • Rule of Law Organizations >
      • Bill of Rights Defense Committee
      • National Lawyers Guild
      • National ACLU
    • Tax Reform Organizations
    • Healthcare for All Organizations >
      • Healthcare is a Human Right - Maryland
      • PNHP Physicians for a National Health Program
      • Healthcare NOW- Maryland
    • Public Education Organizations >
      • Parents Across America
      • Philadelphia Public School Notebook thenotebook.org
      • Chicago Teachers Union/Blog
      • Ed Wize Blog
      • Educators for a Democratic Union
      • Big Education Ape
    • Elections Organizations >
      • League of Women Voters
  • Progressive Actions
    • Labor Actions
    • Justice Actions
    • Tax Reform Actions >
      • Baltimore Tax Actions
      • Maryland Tax Reform Actions
    • Healthcare Actions
    • Public Education Actions
    • Rule of Law Actions >
      • Suing Federal and State government
    • Free and Fair Elections Actions
  • Maryland/Baltimore Voting Districts - your politicians and their votes
    • 2014 ELECTION OF STATE OFFICES
    • Maryland Assembly/Baltimore
  • Petitions, Complaints, and Freedom of Information Requests
    • Complaints - Government and Consumer >
      • Sample Complaints
    • Petitions >
      • Sample Petitions
    • Freedom of Information >
      • Sample Letters
  • State of the Democratic Party
  • Misc
    • WBFF TV
    • WBAL TV
    • WJZ TV
    • WMAR TV
    • WOLB Radio---Radio One
    • The Gazette
    • Baltimore Sun Media Group
  • Misc 2
    • Maryland Public Television
    • WYPR
    • WEAA
    • Maryland Reporter
  • Misc 3
    • University of Maryland
    • Morgan State University
  • Misc 4
    • Baltimore Education Coalition
    • BUILD Baltimore
    • Church of the Great Commission
    • Maryland Democratic Party
    • Pennsylvania Avenue AME Zion Church
    • Maryland Municipal League
    • Maryland League of Women Voters
  • Untitled
  • Untitled
  • Standard of Review
  • Untitled
  • WALSH FOR GOVERNOR - CANDIDATE INFORMATION AND PLATFORM
    • Campaign Finance/Campaign donations
    • Speaking Events
    • Why Heather Mizeur is NOT a progressive
    • Campaign responses to Community Organization Questionnaires
    • Cindy Walsh vs Maryland Board of Elections >
      • Leniency from court for self-representing plaintiffs
      • Amended Complaint
      • Plaintiff request for expedited trial date
      • Response to Motion to Dismiss--Brown, Gansler, Mackie, and Lamone
      • Injunction and Mandamus
      • DECISION/APPEAL TO SPECIAL COURT OF APPEALS---Baltimore City Circuit Court response to Cindy Walsh complaint >
        • Brief for Maryland Court of Special Appeals >
          • Cover Page ---yellow
          • Table of Contents
          • Table of Authorities
          • Leniency for Pro Se Representation
          • Statement of Case
          • Questions Presented
          • Statement of Facts
          • Argument
          • Conclusion/Font and Type Size
          • Record Extract
          • Appendix
          • Motion for Reconsideration
          • Response to Defendants Motion to Dismiss
          • Motion to Reconsider Dismissal
      • General Election fraud and recount complaints
    • Cindy Walsh goes to Federal Court for Maryland election violations >
      • Complaints filed with the FCC, the IRS, and the FBI
      • Zapple Doctrine---Media Time for Major Party candidates
      • Complaint filed with the US Justice Department for election fraud and court irregularities.
      • US Attorney General, Maryland Attorney General, and Maryland Board of Elections are charged with enforcing election law
      • Private media has a responsibility to allow access to all candidates in an election race. >
        • Print press accountable to false statement of facts
      • Polling should not determine a candidate's viability especially if the polling is arbitrary
      • Viability of a candidate
      • Public media violates election law regarding do no damage to candidate's campaign
      • 501c3 Organizations violate election law in doing no damage to a candidate in a race >
        • 501c3 violations of election law-----private capital
      • Voter apathy increases when elections are not free and fair
  • Maryland Board of Elections certifies election on July 10, 2014
  • Maryland Elections ---2016

September 23rd, 2015

9/23/2015

0 Comments

 
I want to spend this entire week speaking on this J-CHIP medical management by microchip that is being developed in Baltimore but will come to all state health systems if it is left to be installed.  First, I want to point out that it is a President running as a progressive liberal toting his desire to help the poor with education and health care-----sending in the most Republican of education and health policies-----and handing Johns Hopkins---the most neo-conservative health institution in the world in a city known to have the worst of health conditions and outcomes-----the green light in what will become a highly abusive health structure for profiteering and far-right health policy.

AGAIN----THEY ARE CALLING ALL OF THIS REPRESSIVE HEALTH POLICY OBAMACARE AND MAKING IT SEEM PROGRESSIVE WHEN THE GOALS ARE MAXIMIZING HEALTH INDUSTRY PROFITS USING WINNING AT ANY COST NEO-LIBERAL POLICY.

These microchip technologies have good applications.  There are people who would want to have this kind of individualized medical oversight------the aging patient who forgets to take meds for example-----the chronically ill who worry about taking meds late or under the wrong biochemical conditions in their bodies.  If this was not the age of global corporate neo-liberalism controlling our government----anything goes with no oversight and accountability----then we could see working these microchip technologies into health care in a responsible way. 

KILLING HIPPOCRATIC OATH KILLS RESPONSIBLE HEALTH CARE.


I want to begin by outing that all of this BIOTech health policy that once functioned in the confines of REAL clinical trials that actually looked out for the welfare of people-----are now totally controlled by people working only to move products to market and maximize profits who fight any attempts at oversight and accountability.  This means----WHAT IS COMING OUT OF CORPORATE UNIVERSITY BIOTECH FACILITIES WILL NOT BE GOOD SCIENCE-----

I worked in medical research for a few decades----I know the processes.  For example, I worked in the development of PCR technology and biomarkers.  I was part of prostate cancer treatment by biotechnology.  Now, almost all of this was funded by Federal NIH and NCI funding and yet----they are patenting these processes and have used them far beyond the time professional data was proving them ineffective.  We heard the same mantra----the development costs for these medical procedures must be recouped.  So, the process in place under Clinton neo-liberals and Republicans under deregulation and no oversight and accountability is to allow medical products to market with little testing to recoup development costs and to monitor symptoms and efficacy on the general population.


Below you see how complex clinical trials have been----all of this trial system is being dismantled as too costly-----and we will not have data that tell us a medical procedure or process does not work---they will only release data that sells the idea that this product helps.

Long-Term Trial Results Show No Mortality Benefit from Annual Prostate Cancer Screening






New data from the Prostate, Lung, Colorectal and Ovarian (PLCO) randomized screening trial show that, after 13 years of follow up, men who underwent annual prostate cancer screening with prostate-specific antigen (PSA) testing and digital rectal examination (DRE) had a 12 percent higher incidence of prostate cancer than men in the control group but the same rate of death from the disease. No evidence of a mortality benefit was seen in subgroups defined by age, the presence of other illnesses, or pre-trial PSA testing. The results were published January 18, 2012, in the Journal of the National Cancer Institute.

When the PLCO researchers published their initial prostate screening results in 2009, which also revealed no prostate cancer mortality or overall mortality benefit from annual screening, critics countered that participants had not been followed long enough to detect a difference in prostate cancer mortality, if one existed.

“The natural history of prostate cancer is so long that 10 to 15 years of follow up is usually the window we look for” when determining the effectiveness of a screening intervention, explained first author Gerald Andriole, M.D., who is chief urologic surgeon at the Siteman Cancer Center at Barnes-Jewish Hospital in St. Louis and the Washington University School of Medicine.


The persistent increase in incidence of prostate cancer in the screening arm of the study may indicate that regular screening can lead to overdiagnosis—finding tumors that never would have caused symptoms or death. “Even if there was just a tiny mortality benefit [from prostate cancer screening], overdiagnosis wouldn’t be so bad if we didn’t hurt people. But we do hurt people by finding a lot of trivial cancers that are most often overtreated,” explained Dr. Andriole.

The PLCO began in 1993 and enrolled men through mid-2001. More than 38,000 men were randomly assigned to annual screening for 6 years (including DRE for the first 4 years and PSA testing for all 6), and the same number of men were assigned to usual care.

Because prostate cancer screening is so common, more than half of the participants in the control arm underwent at least one prostate cancer screening test outside the trial. This contamination made it more difficult to determine whether annual testing affected mortality. However, “the level of screening in the intervention arm was substantially greater than that in the control arm throughout the trial screening period,” wrote the authors.

“Every time we screened [in the intervention arm] we got a bump of excess cases,” said Philip Prorok, Ph.D., a lead NCI investigator on the study. “What we can’t say for sure is whether we would have seen more of an effect on mortality had there been absolutely no screening in the control arm.”

Another recent large trial, called the European Randomized Study of Screening for Prostate Cancer, did report a mortality benefit for prostate cancer screening. Although that trial had less contamination in the control arm, it had other limitations that could bias the results, such as differences in the treatments given to men in the screening and control arms.

To help reconcile the differing results from these two trials—the largest trials to date of organized prostate cancer screening—an effort is under way by the NCI-funded Cancer Intervention and Surveillance Modeling Network (CISNET) to use mathematical modeling to tease out how differences in the trial designs and populations may have contributed to the disparate trial results, explained Paul Pinsky, Ph.D., an NCI investigator on the PLCO trial and consultant to the CISNET project.

“Even though the results seem to be disparate, because one [trial] found a [statistically] significant protective effect [on prostate cancer mortality] and one didn’t, it could be because of the ways the trials were designed and carried out,” he said. The CISNET study began in 2011 and is examining data from the two trials.


Men and their health providers agree that a more definitive answer is needed as doctors and policy makers seek to understand which, if any, men may benefit from routine prostate cancer screening
. In October 2011, the United States Preventive Services Task Force released new draft guidelines for prostate cancer screening for public comment. The new draft guidelines, which are based in part on PLCO findings, recommend against routine PSA testing in men who do not have prostate cancer symptoms.

Some doctors think the new recommendations go too far in not accounting for the informed decisions of individual men. “If prostate cancer constitutes a continuum of disease and its overdiagnosis and overtreatment are mainly limited to low-grade disease, then instead of completely eliminating the potential benefits of screening along with the risks, why not consider managing low-risk patients differently?” asked Jeri Kim, M.D., and John W. Davis, M.D., of the University of Texas M. D. Anderson Cancer Center in a commentary published December 28, 2011, in JAMA.

Practice appears to be moving in this direction, with a greater emphasis on active surveillance instead of immediate treatment for some men who have prostate cancer that is thought to be at low risk of progressing. A big advance, explained Dr. Andriole, would be the ability to predict, even before a biopsy, whether a man with an elevated PSA level is likely to have an aggressive versus a nonaggressive cancer.

“There’s a lot of effort now being put into this, and not just for prostate cancer, but for a lot of other cancer types as well,” added Dr. Prorok. “If we diagnose someone with symptoms, or you find something on a screening test, can we eventually find a way to determine for which individuals the cancers are in fact aggressive and need more aggressive treatment, versus some that need less aggressive treatment or don’t need any treatment at all?”

Researchers are looking for biomarkers, including genes and proteins, that may give clues to a cancer’s aggressiveness. “If we could selectively change our criteria for biopsy such that only men who are at high risk for aggressive cancer get biopsied, we might be able to substantially shift the overall risk/benefit [ratio] of screening,” said Dr. Andriole.


  • Posted: February 17, 2012

    _________________________________________

  • This is a long article but if you glance through you will see what is an industry being built and released to the public BEFORE all of the foundation principles are identified and validated.  These medical processes are now structured like computer technology where the drive is to roll out one product after the other with no research as to whether it is a positive value for society or if these technologies will be used for the public good.  THERE IS NO ETHOS OR MORAL DISCUSSION HAPPENING AT ALL.  Social democratic principles built all that oversight and accountability and a clinical trial structure that made sure all sides of medical advancement were studied-----Clinton neo-liberals and Republicans deregulated and dismantled all this because the goal is to get new products to market....bad effects will be mitigated with money payoffs as always.

    The most blaring issues raised by this article and it is the number 1 reason people do not like Federal funding and public health involved in all this-----IT IS VERY COSTLY BECAUSE IT TARGETS SPECIFIC GENETIC CHARACTERISTICS THAT MAKE EACH TREATMENT UNIQUE TO A SMALL GROUP OF PEOPLE.  INDIVIDUALIZED MEDICINE WILL ONLY BE AFFORDED BY AFFLUENT PEOPLE WITH THE HIGHEST LEVEL OF PRIVATE INSURANCE.

    Fast forward to BIOTech facilities tied to mostly Ivy League universities geared to global health tourism. Meanwhile, over 80% of Americans are being tied to these telemedicine-----microchip level of care.  THE ENTIRE PROCESS IS BACKWARDS BEING BUILT FOR VERY FEW.  It does not take a rocket scientist to know that these techologies will be made main stream and be given over and over again earning billions of dollars for corporations and then we will see the data that shows most of those tests proved/improved nothing.  This is because they are not taking the time to develop the basic science.

    MEANWHILE, LAW FIRMS TIED TO MEDICAL MALPRACTICE HAVE CLASS ACTION LAWSUITS SOARING FOR BAD MEDICINE----THEY EVEN HAVE THIS CATEGORY----BAD MEDICINE.



Biotechnol Healthc. 2004 May; 1(2): 37–41. PMCID: PMC3555164
Explaining The Cost Of Biotech Therapies

BILL EDELMAN



ALL OR NOTHING“The biotech drug market is different from the traditional retail market, in that you have high-cost drugs and few people taking them. Many of these are orphan-status drugs that get propelled through the FDA approval process as a result,” says Greg S. Weishar, president and CEO of PharmaCare Management Services, a pharmacy benefit manager and parent company of PharmaCare Specialty Pharmacy. “Health plans are in the insurance business, and they’re in a dilemma. They’re trying to control costs, and these drugs have very few alternatives.”

Weishar gives this example: For multiple sclerosis, there are few, if any, viable therapeutic alternatives to interferon β-1a (Avonex or Rebif) — the gold standard for MS patients for MCOs.

When the MCO must choose between a chemical therapy and a biotech therapy, the principal variables to weigh are safety, efficacy, and cost. But when the choice is between covering a biotech therapy or providing no viable coverage, the equation is simpler, because depriving an MS patient of the only effective treatment available invites a public relations disaster.

Though only a few patients in a given plan population are diagnosed each year, Weishar observes, the MCO providing this therapy takes a big financial hit.

“At its most fundamental level, insurance is about taking care of people who have a very expensive condition to treat. That’s what it is all about; insurance is catastrophic,” Weishar says. “It’s a question of risk exposure to the insurance company. Only 1 percent of its population needs the drug. The question is, how should the insurance company or health plan manage that 1 percent of covered members who need Avonex [or Rebif]? Probably, the best way to manage those patients is to give them the drug.”

Jeff Kimmell, RPh, vice president and general manager of pharmacy for drugstore.com, agrees that the nature of orphan biotech drugs means that they have an easier path through the MCO approval process: “Uniqueness buys you something, though MCOs will still question whether the patient needs that particular drug. If you can find the item that is unique and provides 5 or 10 percent more effectiveness or 5 to 10 percent fewer side effects, that is what patients will want and physicians will demand. If physicians tell the MCOs, ‘Don’t make me jump through hoops; this is, far and away, the better product,’ the MCOs will start paying for it without question.”

VIABLE OPTIONS

In contrast to Avonex, omalizumab (Xolair) has multiple competitors and is used to treat a common condition, asthma. “Because there are some quite good treatment alternatives for asthma, step therapy is a viable strategy and health plans have the ability to winnow that one tenth of 1 percent of asthma patients who really need Xolair,” Weishar points out. At $700 per prescription, Xolair is reserved for those few patients who cannot obtain acceptable results using chemical-based options.

Indications for the use of biotech drugs are expanding, and physicians are prescribing them increasingly. Joel Owerbach, PharmD, vice president and chief pharmacy officer for Excellus BlueCross/BlueShield estimates that the expense of biotech drug therapy increases by 30 to 50 percent annually. To decrease waste and its inherent expense, ensuring appropriate use is vital. “We need to evaluate whether a person should get the drug, determine who has the best chance of responding to it, and make sure we get the best return on the investment, which means getting the best outcome,” Owerbach says. “We need adequate proof that the patient is responding to treatment, the drug is controlling the condition, and the patient is going to avoid complications later.”

Kimmell likens this paradigm to the emergence of the earliest mass-market drugs. “When we first developed traditional pharmaceuticals, we were able to develop a few strains to take care of everybody and his brother. Anybody in the world who had an infection was able to take penicillin and get better,” Kimmell observes. “Then we had to make erythromycin because of penicillin allergies. Now, we’ve progressed to biotechnological drugs.”

Pharmacogenomics likely will yield effective drugs to people with similar genetic make-ups. Despite physical differences, persons can be so genetically alike that they can be grouped; a drug custom-designed to produce positive clinical outcomes in them may not be as effective for other genetic types. Yet finding patients who will respond best to a specific therapy necessitates biologic assays costing $100 to $700 or more. Many assays are either not covered by health plans or are covered at the Medicare rate — which often amounts to a fraction of the cost of the test.

______________________________________________
Not many people know or understand what has been the focus of medical research for two decades-----with Wall Street corporations bought and sold like crazy.  BioTechnology has taken the concept I show above-----finding genetic markers and then targeting those markers with different treatments----sometimes involving light, chemicals, and even living combatants.  These technologies are as interesting as all nanotech and robotics being installed.  The problem falls in the variability and arbitrary nature of these processes.  PHARMA used a chemical compound as in aspirin that was known to migrate through body systems to the point of inflamation.....the precision needed for these new technologies----and the specificity of applications to individuals and treatment will assure problems for far into the future----a few decades let's say.  The J-CHIP being developed by Johns Hopkins seeks to integrate what is an already complex set of biotechnical activities. 

When Hopkins says it is taking these technologies out into Baltimore's underserved communities for testing and development----we are talking very serious medical invasion.  Just the faith in a technology's reliability in releasing whatever chemical treatment into someone's body remotely -------and then the measurements and data capture-----can be a great risk.  Not to mention the intent to use treatments that are as of yet not proven efficacious.... meaning providing improvement.



HOW MUCH CLINICAL TRIAL TESTING ON HUMANS HAS THESE TECHNOLOGIES HAD -----OR IS THIS MOSTLY LAB TESTED? 

We have no Federal public health or Baltimore City public health reporting these figures that I know of.
  IMEC below is a partner global corporation in these technology applications ----having a broad field of applications including human body tracking.  We know it is these corporations and their data being presented as successful -----and the Federal government whether Department of Health and Human Services or the Food and Drug Administration are NOT LOOKING AT THE VALIDITY OF THESE DATA.


About IMEC Technologies


IMEC Technologies is a supplier of data collection and Track and Trace solutions for use in regulated industries and healthcare environments. Our customers include some of the world’s leading organisation including Pfizer, American Airlines, Kerry Group and GlaxoSmithKline. Headquartered in Urbana, Illinois the company also has development and sales offices in the UK and Ireland.

IMEC Technologies’ solutions include

  • HazMat T&T, a Waste Management system used to track and trace all waste streams within organizations such as hospitals, oil and gas companies, chemical and pharmaceutical companies;
  • Inspector T&T a web based inspection system that will schedule, track, manage and report on any type of equipment, asset, location inspection or audit on a predefined planned schedule or on and ad hoc basis;
  • Navigation Material Movements, an RF Material Tracking System to track and report on material movements within a manufacturing company, Navigation Enterprise Labelling(NEL) which is a FDA and GMP compliant label design, approval, control, printing and reconciliation system for use in life science industries.





Biomedical chip technology: Small but powerful tools for our health


By Kris Verstreken, MD, PhD and Hanne Degans, PhD –  Imec


March 9, 2011 — How will nanoelectronics and nanotechnology contribute to prevention, diagnosis, therapy and post therapy of diseases? Will the introduction of nanoelectronics in pharmacy bring a breakthrough in developing revolutionary therapies such as immuno- or gene therapy? The continued scaling of chip technology resulted in nanoelectronics dimensions evolving increasingly toward cell dimensions, cell parts, and even molecules. As a result, electronic and biological functions can interact, and new applications arise in the area of biomedical electronics.

Biosensor technologies combining a biological identifying element (protein, DNA/RNA, virus, cell) with a physicochemical detector component are widely applicable in drug development at all stages of the development track (from lab to clinical tests), for localized therapy, for inexpensive and comfortable tools for post-therapy, for early diagnosis (genetic profiling) and even for prevention. Innovative biosensors based on nanoelectronics and nanotechnology will be key to creating a better, patient-oriented and less expensive healthcare in the future.

The pharmaceutical industry’s interest in disease diagnosis is growing. These days, diagnosis is being carried out especially by post-symptomatic analysis and diagnosis in laboratories. In the future, technologies based on nano-electronics will enable diagnosis by means of genetic or other early screening of patients, and therapies will be administered with personalized observation. Biomedical electronics will also improve treatment efficiencies and reduce its costs. Sensor-based technologies will enable localized therapy, only intervening when necessary and reducing the side effects of a treatment. Post-therapy based on nanoelectronics will be less burdensome on the daily life of the patient. Such instruments should be low-cost, portable, and comfortable in maintenance and operation.

An essential aspect for the pharmaceutical industry is that new measuring methods are not only fast and efficient; they should also be widely applicable and therefore can be produced in large volumes at reasonable cost. The industry is looking for instruments that can be used not only for drug development, but also during the post-therapeutic stage, to keep an eye on the patients that participated in the clinical tests for drug development. These instruments that will be used for genetic profiling for disease diagnosis and prevention.



Figure. General concept of a biosensor to detect a target in blood.

New measuring methods using nanoelectronics-based biosensors are of key interest to the pharmaceutical industry because of the variety of applications. They are useful for diagnosis, but also in lab studies (genetic profiling), for preclinical and clinical tests, and for therapy and post therapy. Molecular biosensors detect a biomarker (antibodies, enzymes, DNA, diseased cells, foreign substances such as radioisotopes) in blood. They allow fast, exact and very specific measurement of a biomarker or of several different biomarkers at the same time. Biomarkers are blood substances that are characteristic for a certain biological condition and therefore can be used to determine diseases. A biomarker can be a genetic code within the DNA that is characteristic for a particular disease; but it can also be a diseased cell, such as a cancer cell. Additionally, biomarkers can be foreign substances such as radio isotopes, which are being injected into the blood to examine, for example, organ functions. In order to detect biomarkers in the blood, a blood sample needs to be analyzed. Currently, time-consuming and expensive lab tests have to be carried out in several steps to detect biomarkers. When molecular biosensors are integrated into an electronic system (lab-on-chip), detection can be done much faster and cheaper. Imec develops lab-on-chip systems, such as a breast cancer diagnostic system that can detect cancer cells.

Chip technology’s role in healthcare has the world’s attention. Nanoelectronics will help more patients than we can today, at a lower cost price and for a larger number of diseases, or at least such is the hope. Imec’s research supports the necessary innovation of biomedical instruments for prevention, diagnosis and therapy. Within its life science program,
imec cooperates with industrial partners for smart electronic systems in order to study diseases, diagnosis and disease therapy: lab-on-chip systems, nanoparticles for treatment of diseases, technologies for intelligent implants, etc.


______________________________________________

This list of research on microchip delivery systems is not all that has been done of course----I simply wanted to show how new all of this is-----below you see the first in  human testing in 2012 for goodness sake.  The rest fall within the last decade.  Clinical trials have historically taken a decade or so and that was not for basic science like this which takes much longer.  Because we have Clinton neo-liberals and Bush neo-cons making all policy about maximizing profit-----the goals here are simply to move products to market as fast as possible and then pay off people getting harmed.

If you are like me----regardless of the efficacy and research ---I do not want to be forced to be involved in remote medicine.  What Affordable Care Act did was to require health insurance and gave corporations the power to tell citizens what they must submit to in order to stay on a health plan.  They will boost the rates if you decline to a point you cannot afford----just as they are pushing all this SMART METER technology on everyone.


Publications Farra, Robert, et al.


"First-in-human testing of a wirelessly controlled drug delivery microchip."
 

Science Translational Medicine 4.122 (2012): 122ra21-122ra21.


This first-in-human clinical trial evaluated the pharmacokinetic profiles of human parathyroid hormone (hPTH(1–34))delivered by the microchip-based implant versus subcutaneous injections. Results indicated that the release profile of hPTH(1–34) from the microchip-based implant was comparable and bioequivalent to the profile of subcutaneous injections. In addition, patients reported positively when surveyed about their implant experience.

Prescott, James H., et al.

"Chronic, programmed polypeptide delivery from an implanted, multireservoir microchip device."


 Nature biotechnology 24.4 (2006): 437-438.
This first-in-animal study evaluated the ability of the microchip-based implant to deliver leuprolide (an analog of a luteinizing hormone-releasing hormone that is marketed for the treatment of prostate cancer and endometriosis) over a 6-month period in dogs. Results supported the feasibility of applying microchip-based implant technology to deliver other therapeutic peptides and proteins. In addition, the study suggested that drug delivery from an array of discrete reservoirs is not restricted to solution-phase drug formulations, and that stability-optimized, solid-phase drug formulations can be packaged and released in vivo.

Grayson, Amy C. Richards, et al.

"Multi-pulse drug delivery from a resorbable polymeric microchip device."
 

Nature materials
 2.11 (2003): 767-772.
The Microchips Biotech IP portfolio includes both electronically-controlled reservoir implants as well as preprogrammed, non-electronic reservoir-based implants, made of resorbable polymers. This study evaluated the functionality of a biodegradable microchip implant and demonstrated that timed, pulsatile delivery is possible by varying the molecular mass of the membranes covering each reservoir.



0 Comments

Your comment will be posted after it is approved.


Leave a Reply.

    Author

    Cindy Walsh is a lifelong political activist and academic living in Baltimore, Maryland.

    Archives

    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    July 2017
    June 2017
    May 2017
    April 2017
    March 2017
    February 2017
    January 2017
    December 2016
    November 2016
    October 2016
    September 2016
    August 2016
    July 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    January 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015
    July 2015
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014
    October 2014
    September 2014
    August 2014
    July 2014
    June 2014
    May 2014
    April 2014
    March 2014
    February 2014
    January 2014
    December 2013
    November 2013
    October 2013
    September 2013
    August 2013
    July 2013
    June 2013
    May 2013
    April 2013
    March 2013
    February 2013
    January 2013
    December 2012
    November 2012
    October 2012
    September 2012
    August 2012
    July 2012
    June 2012
    May 2012
    April 2012

    Categories

    All
    2014 Economic Crash
    21st Century Economy
    Affordable Care Act
    Affordable Care Act
    Alec
    Americorp/VISTA
    Anthony Brown
    Anthony Brown
    Anti Incumbant
    Anti-incumbant
    Anti Incumbent
    Anti Incumbent
    Attacking The Post Office Union
    Baltimore And Cronyism
    Baltimore Board Of Estimates
    Baltimore Board Of Estimates
    Baltimore Development Corp
    Baltimore Development Corp
    Baltimore Recall/Retroactive Term Limits
    Bank Fraud
    Bank Fraud
    Bank Of America
    Bank Settlement
    Bank-settlement
    B Corporations
    Bgeexelon Mergerf59060c411
    Brookings Institution
    Business Tax Credits
    California Charter Expansion
    Cardin
    Career Colleges
    Career Colleges Replacing Union Apprenticeships
    Charters
    Charter School
    Collection Agencies
    Common Core
    Consumer Financial Protection Bureau
    Consumer-financial-protection-bureau
    Corporate Media
    Corporate-media
    Corporate Oversight
    Corporate-oversight
    Corporate Politicians
    Corporate-politicians
    Corporate Rule
    Corporate-rule
    Corporate Taxes
    Corporate-taxes
    Corporate Tax Reform
    Corporatizing Us Universities
    Cost-benefit-analysis
    Credit Crisis
    Credit-crisis
    Cummings
    Department Of Education
    Department Of Justice
    Department-of-justice
    Derivatives Reform
    Development
    Dismantling Public Justice
    Dodd Frank
    Doddfrankbba4ff090a
    Doug Gansler
    Doug-gansler
    Ebdi
    Education Funding
    Education Reform
    Edwards
    Election Reform
    Election-reform
    Elections
    Emigration
    Energy-sector-consolidation-in-maryland
    Enterprise Zones
    Equal Access
    Estate Taxes
    European Crisis
    Expanded And Improved Medicare For All
    Expanded-and-improved-medicare-for-all
    Failure To Prosecute
    Failure-to-prosecute
    Fair
    Fair And Balanced Elections
    Fair-and-balanced-elections
    Farm Bill
    Federal Election Commissionelection Violationsmaryland
    Federal Election Commissionelection Violationsmarylandd20a348918
    Federal-emergency-management-agency-fema
    Federal Reserve
    Financial Reform Bill
    Food Safety Not In Tpp
    For Profit Education
    Forprofit-education
    Fracking
    Fraud
    Freedom Of Press And Speech
    Frosh
    Gambling In Marylandbaltimore8dbce1f7d2
    Granting Agencies
    Greening Fraud
    Gun Control Policy
    Healthcare For All
    Healthcare-for-all
    Health Enterprise Zones
    High Speed Rail
    Hoyer
    Imf
    Immigration
    Incarceration Bubble
    Incumbent
    Incumbents
    Innovation Centers
    Insurance Industry Leverage And Fraud
    International Criminal Court
    International Trade Deals
    International-trade-deals
    Jack Young
    Jack-young
    Johns Hopkins
    Johns-hopkins
    Johns Hopkins Medical Systems
    Johns-hopkins-medical-systems
    Kaliope Parthemos
    Labor And Justice Law Under Attack
    Labor And Wages
    Lehmann Brothers
    Living Wageunionspolitical Action0e39f5c885
    Maggie McIntosh
    Maggie-mcintosh
    Martin O'Malley
    Martin O'Malley
    Martin-omalley
    Martin-omalley8ecd6b6eb0
    Maryland Health Co Ops
    Maryland-health-co-ops
    Maryland-health-co-ops1f77692967
    Maryland Health Coopsccd73554da
    Maryland Judiciary
    Marylandnonprofits
    Maryland Non Profits
    Maryland Nonprofits2509c2ca2c
    Maryland Public Service Commission
    Maryland State Bar Association
    Md Credit Bondleverage Debt441d7f3605
    Media
    Media Bias
    Media-bias
    Medicaremedicaid
    Medicaremedicaid8416fd8754
    Mental Health Issues
    Mental-health-issues
    Mers Fraud
    Mikulski
    Military Privatization
    Minority Unemploymentunion And Labor Wagebaltimore Board Of Estimates4acb15e7fa
    Municipal Debt Fraud
    Ndaa-indefinite-detention
    Ndaaindefinite Detentiond65cc4283d
    Net Neutrality
    New Economy
    New-economy
    Ngo
    Non Profit To Profit
    Nonprofit To Profitb2d6cb4b41
    Nsa
    O'Malley
    Odette Ramos
    Omalley
    O'Malley
    Open Meetings
    Osha
    Patronage
    Pension-benefit-guaranty-corp
    Pension Funds
    Pension-funds
    Police Abuse
    Private-and-public-pension-fraud
    Private Health Systemsentitlementsprofits Over People
    Private Health Systemsentitlementsprofits Over People6541f468ae
    Private Non Profits
    Private-non-profits
    Private Nonprofits50b33fd8c2
    Privatizing Education
    Privatizing Government Assets
    Privatizing-the-veterans-admin-va
    Privitizing Public Education
    Progressive Policy
    Progressive Taxes Replace Regressive Policy
    Protections Of The People
    Protections-of-the-people
    Public Education
    Public Funding Of Private Universities
    Public Housing Privatization
    Public-libraries-privatized-or-closed
    Public Private Partnerships
    Public-private-partnerships
    Public Transportation Privatization
    Public Utilities
    Rapid Bus Network
    Rawlings Blake
    Rawlings-blake
    Rawlingsblake1640055471
    Real Progressives
    Reit-real-estate-investment-trusts
    Reitreal Estate Investment Trustsa1a18ad402
    Repatriation Taxes
    Rule Of Law
    Rule-of-law
    Ruppersberger
    SAIC AND INTERNATIONAL SECURITY
    Sarbanes
    S Corp Taxes
    Selling Public Datapersonal Privacy
    Smart Meters
    Snowden
    Social Security
    Sovereign Debt Fraudsubprime Mortgage Fraudmortgage Fraud Settlement
    Sovereign Debt Fraudsubprime Mortgage Fraudmortgage Fraud Settlement0d62c56e69
    Statistics As Spin
    Statistics-as-spin
    Student-corps
    Subprime Mortgage Fraud
    Subprime-mortgage-fraud
    Surveillance And Security
    Sustainability
    Teachers
    Teachers Unions2bc448afc8
    Teach For America
    Teach For America
    Technology Parks
    Third Way Democrats/new Economy/public Union Employees/public Private Patnerships/government Fraud And Corruption
    Third Way Democratsnew Economypublic Union Employeespublic Private Patnershipsgovernment Fraud And Corruption
    Third-way-democratsnew-economypublic-union-employeespublic-private-patnershipsgovernment-fraud-and-corruptionc10a007aee
    Third Way/neo Liberals
    Third-wayneo-liberals
    Third-wayneo-liberals5e1e6d4716
    Third Wayneoliberals7286dda6aa
    Tifcorporate Tax Breaks2d87bba974
    Tpp
    Transportation Inequity In Maryland
    Union Busting
    Unionbusting0858fddb8b
    Unions
    Unionsthird Waypost Officealec3c887e7815
    Universities
    Unreliable Polling
    Unreliable-polling
    Van Hollen
    Van-hollen
    VEOLA Environment -privatization Of Public Water
    Veterans
    War Against Women And Children
    War-against-women-and-children
    Youth Works

    RSS Feed

Powered by Create your own unique website with customizable templates.